Tirzepatide (Mounjaro, Zepbound) and Ketamine Therapy | Tovani Health
Mounjaro (Tirzepatide) (also: Zepbound) — Dual GIP/GLP-1 receptor agonist (weight loss / type 2 diabetes)
Verdict at Tovani Health
Fully compatible with KAP; same profile as semaglutide.
Tirzepatide and ketamine have no clinically significant interaction. Mounjaro (diabetes) and Zepbound (weight loss) are the same molecule, and both work fine alongside ketamine therapy.
If you take Mounjaro regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Mounjaro interacts with ketamine
Tirzepatide agonizes both GIP and GLP-1 receptors. Like semaglutide, it slows gastric emptying and improves glycemic control. No overlap with ketamine pharmacology.
What we do at intake
Continue as normal. Disclose GI side effects so we can prophylax with ondansetron if needed.
Bottom line
Tirzepatide and ketamine have no clinically significant interaction. Mounjaro (diabetes) and Zepbound (weight loss) are the same molecule, and both work fine alongside ketamine therapy.
Frequently Asked Questions
Is Mounjaro the same as Zepbound for KAP purposes?
Yes, identical molecule. Same compatibility profile.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Mounjaro (Tirzepatide) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide). Manoharan SVRR, et al.. Innovations in Clinical Neuroscience. 2024. PMID: 38938530
Case report of worsened depression on semaglutide — relevant to GLP-1 + ketamine intake screening.
- Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535
Comprehensive clinical pharmacokinetics/pharmacodynamics review of ketamine including CYP-mediated drug interactions (CYP3A4, CYP2B6).
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.